Sarepta Therapeutics - SRPT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $156.60
Forecasted Upside: 21.61%
Number of Analysts: 14
Breakdown:
0 Sell Ratings
3 Hold Ratings
11 Buy Ratings
0 Strong Buy Ratings

^$128.77 As of 04/26/2024 01:00 AM ET

▲ +1.38 (1.08%)

1 month | 3 months | 12 months

Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

^$156.60

▲ +21.61% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $156.60, with a high forecast of $224.00 and a low forecast of $109.00. The average price target represents a 21.61% upside from the last price of $128.77.

Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Sarepta Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/5/2022

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/3/2023

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/4/2023

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

8/2/2023

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/31/2023

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/29/2024

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/29/2024

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/28/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/1/2024	UBS Group	Boost Target	Buy ➝ Buy	$164.00 ➝ $167.00	Low
2/29/2024	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$128.00	Low
2/29/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$151.00 ➝ $157.00	Low
2/29/2024	Wedbush	Reiterated Rating	Outperform	$224.00	Low
2/29/2024	Citigroup	Boost Target	Buy ➝ Buy	$160.00 ➝ $172.00	Low
2/29/2024	Barclays	Boost Target	Overweight ➝ Overweight	$141.00 ➝ $185.00	Low
2/29/2024	Needham & Company LLC	Lower Target	Buy ➝ Buy	$169.00 ➝ $166.00	Low
2/20/2024	Evercore ISI	Boost Target	In-Line ➝ In-Line	$108.00 ➝ $138.00	Low
2/20/2024	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$224.00	Low
2/16/2024	Needham & Company LLC	Boost Target	Buy ➝ Buy	$140.00 ➝ $169.00	Low
2/14/2024	Mizuho	Boost Target	Buy ➝ Buy	$130.00 ➝ $145.00	Low
2/14/2024	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$128.00	Low
1/31/2024	BMO Capital Markets	Initiated Coverage	Outperform	$170.00	Low
1/29/2024	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$224.00	Low
1/29/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$140.00	Low
1/25/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$155.00 ➝ $151.00	Low
1/10/2024	Needham & Company LLC	Boost Target	Buy ➝ Buy	$93.00 ➝ $140.00	Low
1/9/2024	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$224.00	Low
12/13/2023	Citigroup	Initiated Coverage	Buy	$113.00	Low
12/12/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$109.00	Low
11/21/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$148.00	Low
11/21/2023	Wedbush	Initiated Coverage	Outperform	$224.00	Low
11/2/2023	Barclays	Lower Target	Overweight ➝ Overweight	$193.00 ➝ $141.00	N/A
10/31/2023	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$211.00 ➝ $115.00	Low
10/31/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$217.00 ➝ $148.00	Low
10/31/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Neutral	$166.00 ➝ $40.00	Low
10/31/2023	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
10/31/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$183.00 ➝ $146.00	Low
10/31/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$185.00 ➝ $82.00	Low
9/26/2023	Mizuho	Reiterated Rating	Buy ➝ Buy	$160.00	Low
8/3/2023	Needham & Company LLC	Reiterated Rating	Buy	$185.00	Low
8/3/2023	Morgan Stanley	Reiterated Rating	Overweight ➝ Overweight	$183.00	Low
8/3/2023	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$221.00 ➝ $223.00	Low
7/14/2023	Morgan Stanley	Reiterated Rating	Overweight ➝ Overweight	$183.00	Low
6/23/2023	Citigroup	Lower Target		$204.00 ➝ $161.00	Low
6/23/2023	JPMorgan Chase & Co.	Lower Target		$217.00 ➝ $213.00	Low
6/23/2023	Bank of America	Boost Target		$176.00 ➝ $186.00	Low
6/23/2023	Barclays	Boost Target		$170.00 ➝ $193.00	Low
5/30/2023	Evercore ISI	Lower Target		$173.00 ➝ $151.00	Low
5/24/2023	Credit Suisse Group	Lower Target		$151.00 ➝ $141.00	Low
5/16/2023	Royal Bank of Canada	Boost Target		$197.00 ➝ $218.00	Low
5/15/2023	Bank of America	Boost Target		$164.00 ➝ $176.00	Low
5/15/2023	UBS Group	Boost Target		$160.00 ➝ $173.00	Low
5/15/2023	Credit Suisse Group	Boost Target		$138.00 ➝ $151.00	Low
5/3/2023	Cantor Fitzgerald	Lower Target		$165.00 ➝ $158.00	Low
4/26/2023	Sumitomo Mitsui Financial Group	Initiated Coverage	Outperform	$185.00	Low
4/14/2023	Mizuho	Reiterated Rating	Buy	$160.00	Low
4/12/2023	Morgan Stanley	Lower Target		$187.00 ➝ $183.00	Low
4/4/2023	Citigroup	Initiated Coverage	Buy ➝ Buy	$179.00	Low
3/22/2023	TD Cowen	Boost Target	Outperform	$125.00 ➝ $175.00	Low
3/17/2023	Royal Bank of Canada	Lower Target	Outperform	$226.00 ➝ $200.00	Low
3/17/2023	Mizuho	Reiterated Rating	Buy	$160.00	Low
3/17/2023	Cantor Fitzgerald	Lower Target		$178.00 ➝ $165.00	Low
3/17/2023	Credit Suisse Group	Lower Target	Neutral	$144.00 ➝ $139.00	Low
3/17/2023	Needham & Company LLC	Lower Target	Buy	$200.00 ➝ $160.00	Low
3/9/2023	Oppenheimer	Lower Target	Outperform	$180.00 ➝ $150.00	Low
3/3/2023	JPMorgan Chase & Co.	Boost Target	Overweight	$153.00 ➝ $206.00	Low
3/1/2023	Needham & Company LLC	Boost Target	Buy	$160.00 ➝ $200.00	Low
3/1/2023	The Goldman Sachs Group	Boost Target	Buy	$171.00 ➝ $190.00	Low
3/1/2023	Royal Bank of Canada	Boost Target	Outperform	$195.00 ➝ $226.00	Low
3/1/2023	Oppenheimer	Boost Target	Outperform	$150.00 ➝ $180.00	Low
3/1/2023	Credit Suisse Group	Boost Target	Neutral	$137.00 ➝ $144.00	Low
3/1/2023	Robert W. Baird	Boost Target	Outperform	$152.00 ➝ $202.00	Low
3/1/2023	Barclays	Boost Target		$149.00 ➝ $170.00	Low
3/1/2023	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$141.00 ➝ $187.00	Low
2/15/2023	Credit Suisse Group	Boost Target	Neutral	$114.00 ➝ $137.00	Low
1/20/2023	SVB Leerink	Reiterated Rating	Outperform	$160.00	Low
1/11/2023	Cowen	Boost Target		$114.00 ➝ $125.00	Low
1/10/2023	Needham & Company LLC	Boost Target	Buy	$158.00 ➝ $160.00	Low
1/10/2023	Credit Suisse Group	Boost Target	Neutral	$101.00 ➝ $114.00	Low
12/22/2022	BTIG Research	Boost Target	Buy	$125.00 ➝ $160.00	Low
12/16/2022	UBS Group	Upgrade	Neutral ➝ Buy	$100.00 ➝ $158.00	Low
12/13/2022	Cantor Fitzgerald	Boost Target		$150.00 ➝ $174.00	Low
11/3/2022	Royal Bank of Canada	Lower Target	Outperform	$193.00 ➝ $190.00	Low
11/3/2022	The Goldman Sachs Group	Boost Target	Buy	$152.00 ➝ $171.00	Low
11/3/2022	Credit Suisse Group	Boost Target	Neutral	$93.00 ➝ $101.00	Low
11/3/2022	Robert W. Baird	Boost Target		$110.00 ➝ $152.00	Low
11/3/2022	Needham & Company LLC	Lower Target	Buy	$162.00 ➝ $158.00	Low
10/17/2022	SVB Leerink	Boost Target	Outperform	$126.00 ➝ $145.00	Low
10/13/2022	Morgan Stanley	Boost Target	Equal Weight	$135.00 ➝ $141.00	Low
9/8/2022	Morgan Stanley	Boost Target	Equal Weight	$100.00 ➝ $135.00	Low
8/9/2022	Royal Bank of Canada	Boost Target	Outperform	$160.00 ➝ $182.00	Low
8/3/2022	Royal Bank of Canada	Boost Target	Outperform	$156.00 ➝ $160.00	N/A
8/3/2022	Guggenheim	Boost Target		$100.00 ➝ $122.00	Low
8/3/2022	Morgan Stanley	Boost Target	Equal Weight	$80.00 ➝ $100.00	Low
8/3/2022	Credit Suisse Group	Boost Target	Neutral	$90.00 ➝ $93.00	Low
8/3/2022	Barclays	Boost Target		$104.00 ➝ $125.00	Low
8/3/2022	Oppenheimer	Boost Target		$125.00 ➝ $150.00	Low
7/29/2022	Needham & Company LLC	Boost Target	Buy	$150.00 ➝ $162.00	Low
6/24/2022	Cantor Fitzgerald	Lower Target	Overweight	$140.00 ➝ $128.00	Low
6/24/2022	Credit Suisse Group	Lower Target	Neutral	$95.00 ➝ $90.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$181.00 ➝ $155.00	Medium
5/19/2022	Morgan Stanley	Lower Target	Equal Weight	$77.00 ➝ $74.00	Low
4/12/2022	Morgan Stanley	Lower Target	Equal Weight	$80.00 ➝ $77.00	Low
3/7/2022	Morgan Stanley	Boost Target	Equal Weight	$71.00 ➝ $80.00	High
3/2/2022	Barclays	Lower Target		$125.00 ➝ $104.00	Medium
3/2/2022	Royal Bank of Canada	Boost Target	Outperform	$145.00 ➝ $150.00	High
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$92.00 ➝ $71.00	Medium
1/18/2022	Morgan Stanley	Boost Target	Equal Weight	$90.00 ➝ $92.00	Low
1/11/2022	Needham & Company LLC	Reiterated Rating	Buy	$150.00	Medium
1/5/2022	Needham & Company LLC	Lower Target	Buy	$157.00 ➝ $150.00	High
12/9/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$125.00	Medium
11/5/2021	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$88.00 ➝ $130.00	Medium
11/4/2021	Cantor Fitzgerald	Boost Target	Overweight	$128.00 ➝ $140.00	High
11/4/2021	Royal Bank of Canada	Lower Target	Outperform	$148.00 ➝ $145.00	High
11/4/2021	Needham & Company LLC	Lower Target	Buy	$166.00 ➝ $157.00	High
10/15/2021	Berenberg Bank	Reiterated Rating	Hold	$90.00	High
10/12/2021	Credit Suisse Group	Boost Target	Neutral	$75.00 ➝ $100.00	High
10/12/2021	SVB Leerink	Reiterated Rating	Buy		High
10/12/2021	Needham & Company LLC	Reiterated Rating	Buy		High
10/12/2021	BTIG Research	Boost Target	Buy	$110.00 ➝ $125.00	High
10/7/2021	Robert W. Baird	Initiated Coverage	Buy	$110.00	Medium
9/15/2021	Guggenheim	Upgrade	Neutral ➝ Buy		High
8/16/2021	Morgan Stanley	Lower Target	Equal Weight	$93.00 ➝ $90.00	High
8/5/2021	Credit Suisse Group	Boost Target	Neutral	$72.00 ➝ $75.00	High
8/5/2021	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$92.00 ➝ $87.00	High
7/1/2021	Berenberg Bank	Initiated Coverage	Hold	$85.00	Medium
6/14/2021	BTIG Research	Initiated Coverage	Buy	$110.00	High
5/3/2021	Needham & Company LLC	Initiated Coverage	Buy	$166.00	High
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$95.00 ➝ $93.00	Low
4/16/2021	William Blair	Reiterated Rating	Buy		Low
3/21/2021	SVB Leerink	Reiterated Rating	Buy		Low
3/2/2021	Royal Bank of Canada	Lower Target	Outperform	$143.00 ➝ $132.00	High
3/2/2021	Needham & Company LLC	Reiterated Rating	Buy	$166.00	High
3/2/2021	SVB Leerink	Boost Target	Outperform	$125.00 ➝ $126.00	High
3/2/2021	Piper Sandler	Lower Target	Neutral	$140.00 ➝ $130.00	High
2/26/2021	Mizuho	Boost Target	Buy	$158.00 ➝ $160.00	High
1/12/2021	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		High
1/11/2021	UBS Group	Downgrade	Buy ➝ Neutral		High
1/8/2021	Oppenheimer	Reiterated Rating	Hold ➝ Neutral		High
1/8/2021	Credit Suisse Group	Lower Target	Neutral	$156.00 ➝ $73.00	N/A
1/8/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Underweight	$96.00	N/A
1/8/2021	Robert W. Baird	Lower Target	Outperform	$223.00 ➝ $110.00	N/A
1/8/2021	Cowen	Lower Target	Outperform	$213.00 ➝ $114.00	N/A
1/8/2021	Needham & Company LLC	Lower Target	Buy	$182.00 ➝ $166.00	N/A
1/8/2021	Barclays	Lower Target	Positive ➝ Overweight	$192.00 ➝ $125.00	N/A
1/8/2021	Cantor Fitzgerald	Lower Target	Overweight	$217.00 ➝ $128.00	N/A
1/8/2021	Royal Bank of Canada	Lower Target	Outperform	$200.00 ➝ $143.00	N/A
1/8/2021	Mizuho	Lower Target	Buy	$204.00 ➝ $158.00	N/A
1/8/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$182.00 ➝ $95.00	N/A
1/8/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
1/8/2021	SVB Leerink	Lower Target	Outperform	$197.00 ➝ $125.00	N/A
1/4/2021	Piper Sandler	Boost Target	Overweight	$200.00 ➝ $240.00	N/A
12/14/2020	Smith Barney Citigroup	Boost Target		$190.00 ➝ $215.00	Low
12/14/2020	Credit Suisse Group	Lower Target	Neutral	$162.00 ➝ $156.00	Medium
12/8/2020	Mizuho	Boost Target	Buy	$192.00 ➝ $204.00	High
11/11/2020	Berenberg Bank	Initiated Coverage	Hold	$140.00	Medium
11/6/2020	Credit Suisse Group	Lower Target	Neutral	$167.00 ➝ $162.00	High
11/6/2020	SVB Leerink	Lower Target	Outperform	$214.00 ➝ $197.00	High
10/28/2020	UBS Group	Initiated Coverage	Buy	$212.00	Low
10/11/2020	Royal Bank of Canada	Reiterated Rating	Buy		Low
9/15/2020	Citigroup	Boost Target	Buy	$177.00 ➝ $190.00	Medium
8/31/2020	HC Wainwright	Lower Target	Buy	$260.00 ➝ $221.00	Low
8/24/2020	Raymond James	Initiated Coverage	Outperform	$200.00	High
8/21/2020	Bank of America	Lower Target	Buy	$190.00 ➝ $189.00	Medium
8/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$185.00 ➝ $167.00	High
8/10/2020	Morgan Stanley	Boost Target	Overweight	$172.00 ➝ $182.00	Low
8/4/2020	Piper Sandler	Lower Target	Overweight	$206.00 ➝ $200.00	Low
8/3/2020	Credit Suisse Group	Reiterated Rating	Buy		Low
6/22/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$160.00 ➝ $190.00	Low
6/16/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	Medium
6/10/2020	Bank of America	Reiterated Rating	Buy	$180.00	High
6/8/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	High
6/8/2020	Robert W. Baird	Reiterated Rating	Buy	$192.00	High
5/17/2020	Nomura	Reiterated Rating	Buy	$230.00	High
5/15/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
5/15/2020	Robert W. Baird	Reiterated Rating	Buy	$192.00	High
5/15/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	High
5/7/2020	Needham & Company LLC	Initiated Coverage	Buy	$182.00	High
5/7/2020	Credit Suisse Group	Reiterated Rating	Buy	$185.00	High
5/7/2020	Oppenheimer	Reiterated Rating	Hold		High
5/6/2020	Royal Bank of Canada	Reiterated Rating	Buy	$182.00	Low
4/30/2020	Mizuho	Reiterated Rating	Buy	$183.00	Low
4/15/2020	Morgan Stanley	Lower Target	Overweight	$173.00 ➝ $172.00	Low
3/30/2020	Mizuho	Initiated Coverage	Buy	$183.00	High
2/28/2020	JPMorgan Chase & Co.	Lower Target	Overweight	$172.00 ➝ $160.00	High
2/27/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$211.00 ➝ $217.00	High
2/27/2020	JMP Securities	Lower Target	Outperform	$280.00 ➝ $217.00	High
2/25/2020	Nomura Securities	Reiterated Rating	Buy	$230.00	High
1/23/2020	SVB Leerink	Reiterated Rating	Buy	$216.00	Low
1/14/2020	Credit Suisse Group	Reiterated Rating	Buy	$185.00	Low
1/14/2020	Cowen	Reiterated Rating	Buy	$213.00	High
1/7/2020	Bank of America	Reiterated Rating	Buy	$187.00	High
12/30/2019	Oppenheimer	Reiterated Rating	Hold		Low
12/26/2019	Citigroup	Reiterated Rating	Buy	$177.00	Low
12/25/2019	Nomura Securities	Reiterated Rating	Buy	$230.00	Low
12/24/2019	The Goldman Sachs Group	Reiterated Rating	Buy	$180.00	Low
12/24/2019	Morgan Stanley	Boost Target	Overweight	$160.00 ➝ $173.00	Low
12/24/2019	Credit Suisse Group	Reiterated Rating	Overweight ➝ Outperform	$190.00 ➝ $185.00	Low
12/23/2019	Piper Sandler Companies	Reiterated Rating	Buy	$210.00	N/A
12/23/2019	Royal Bank of Canada	Lower Target	Outperform	$215.00 ➝ $200.00	Medium
12/20/2019	Robert W. Baird	Boost Target	Outperform	$181.00 ➝ $192.00	Low
12/18/2019	Nomura Securities	Reiterated Rating	Buy	$230.00	Low
12/17/2019	Citigroup	Boost Target	Buy	$167.00 ➝ $177.00	Low
12/15/2019	Cowen	Initiated Coverage	Buy	$213.00	Medium
12/15/2019	Barclays	Reiterated Rating	Buy	$202.00	Medium
12/13/2019	HC Wainwright	Boost Target		$160.00 ➝ $260.00	Low
12/13/2019	Cantor Fitzgerald	Boost Target	Overweight	$175.00 ➝ $211.00	High
12/13/2019	SVB Leerink	Reiterated Rating	Outperform	$186.00 ➝ $216.00	Medium
12/13/2019	Piper Sandler Companies	Reiterated Rating	Buy	$185.00 ➝ $210.00	High
12/13/2019	Credit Suisse Group	Boost Target	Outperform	$185.00 ➝ $190.00	High
12/13/2019	Janney Montgomery Scott	Boost Target	Buy	$160.00 ➝ $175.00	High
12/13/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$215.00	High
11/18/2019	Citigroup	Lower Target	Buy ➝ Positive	$180.00 ➝ $167.00	Low
11/8/2019	Credit Suisse Group	Lower Target	Outperform	$201.00 ➝ $185.00	High
11/1/2019	Guggenheim	Initiated Coverage	Buy	$183.00	High
10/11/2019	Morgan Stanley	Lower Target	Overweight	$220.00 ➝ $160.00	Low
10/8/2019	Oppenheimer	Reiterated Rating	Hold		Low
9/27/2019	Piper Sandler Companies	Set Target	Buy	$185.00	Low
9/27/2019	Citigroup	Lower Target	Buy	$185.00 ➝ $180.00	Medium
9/24/2019	Royal Bank of Canada	Set Target	Buy	$204.00	High
9/13/2019	HC Wainwright	Set Target	Buy	$160.00	Low
8/21/2019	Needham & Company LLC	Lower Target	Buy	$196.00 ➝ $170.00	Low
8/20/2019	Royal Bank of Canada	Lower Target	Outperform	$204.00	Low
8/20/2019	Cantor Fitzgerald	Lower Target	Overweight	$231.00 ➝ $175.00	Low
8/20/2019	Robert W. Baird	Lower Target	Outperform	$202.00 ➝ $181.00	High
8/20/2019	Bank of America	Lower Target	Buy	$200.00 ➝ $189.00	High
8/20/2019	Credit Suisse Group	Lower Target	Outperform	$207.00 ➝ $201.00	High
8/20/2019	Janney Montgomery Scott	Lower Target	Buy	$200.00 ➝ $175.00	High
8/20/2019	HC Wainwright	Reiterated Rating	Buy	$160.00 ➝ $267.00	High
8/20/2019	Piper Sandler Companies	Lower Target	Overweight	$208.00 ➝ $185.00	High
8/9/2019	William Blair	Reiterated Rating	Buy		Low
8/8/2019	Evercore ISI	Reiterated Rating	Buy	$200.00	High
7/9/2019	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$165.00 ➝ $220.00	Medium
7/1/2019	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$188.00 ➝ $220.00	Low
6/17/2019	HC Wainwright	Set Target	Buy	$267.00	Low
5/16/2019	Citigroup	Lower Target	Buy	$201.00 ➝ $190.00	Medium
5/14/2019	Morgan Stanley	Lower Target	Overweight	$169.00 ➝ $165.00	Medium
5/9/2019	Royal Bank of Canada	Lower Target	Outperform	$191.00 ➝ $188.00	High

(Data available from 4/28/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

19 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2023

7 very positive mentions
10 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

10/31/2023

11 very positive mentions
19 positive mentions
4 negative mentions
4 very negative mentions

Mentions as of

11/30/2023

15 very positive mentions
13 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/30/2023

25 very positive mentions
20 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

1/29/2024

33 very positive mentions
45 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

2/28/2024

19 very positive mentions
18 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/29/2024

15 very positive mentions
16 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

4/28/2024

Current Sentiment

Recent Stories by Sentiment

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $128.77

$125.62

$131.46

50 Day Range

MA: $126.11

$115.62

$141.53

52 Week Range

Now: $128.77

$55.25

$159.89

Volume

1,236,000 shs

Average Volume

685,718 shs

Market Capitalization

$12.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?: The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, StockNews.com, TheStreet, UBS Group AG, and Wedbush.
View the latest analyst ratings for SRPT.
What is the current price target for Sarepta Therapeutics?: 15 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $156.60, suggesting a possible upside of 21.6%. Wedbush has the highest price target set, predicting SRPT will reach $224.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $109.00 for Sarepta Therapeutics in the next year.
View the latest price targets for SRPT.
What is the current consensus analyst rating for Sarepta Therapeutics?: Sarepta Therapeutics currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SRPT.
What other companies compete with Sarepta Therapeutics?: Other companies that are similar to Sarepta Therapeutics include United Therapeutics, Catalent, Dr. Reddy's Laboratories, Karuna Therapeutics and Roivant Sciences. Learn More about companies similar to Sarepta Therapeutics.
How do I contact Sarepta Therapeutics' investor relations team?: Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 274-4000 and its investor relations email address is [email protected]. The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. Learn More about contacing Sarepta Therapeutics investor relations.

Sarepta Therapeutics - SRPT Stock Price Target and Predictions

Analyst Price Target for SRPT

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.71 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

What is the current price target for Sarepta Therapeutics?

What is the current consensus analyst rating for Sarepta Therapeutics?

What other companies compete with Sarepta Therapeutics?

How do I contact Sarepta Therapeutics' investor relations team?